Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
topic_facet:"Medical Condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism."
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Long-term+prevention+of+recurrent+symptomatic+venous+thromboembolism+in+patients+with+symptomatic+deep-vein+thrombosis+or+pulmonary+embolism.%22&lookfor=%22Thrombosis%22&type=Subject
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Long-term+prevention+of+recurrent+symptomatic+venous+thromboembolism+in+patients+with+symptomatic+deep-vein+thrombosis+or+pulmonary+embolism.%22&lookfor=%22Thrombosis%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Long-term+prevention+of+recurrent+symptomatic+venous+thromboembolism+in+patients+with+symptomatic+deep-vein+thrombosis+or+pulmonary+embolism.%22&lookfor=%22Thrombosis%22&type=Subject
PubPharm (24)
1
Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
2
Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
3
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. Rivaroxaban oral, una vez al día, inhibidor directo del factor Xa en la prevención a largo plazo del trombo embolismo venoso sintomático recurrente, en pacientes con trombosis venosa profunda, o embolia pulmonar sintomáticas. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. Rivaroxaban oral, una vez al día, inhibidor directo del factor Xa en la prevención a largo plazo del trombo embolismo venoso sintomático recurrente, en pacientes con trombosis venosa profunda, o embolia pulmonar sintomáticas. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
4
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. Rivaroxaban oral, una vez al día, inhibidor directo del factor Xa en la prevención a largo plazo del trombo embolismo venoso sintomático recurrente, en pacientes con trombosis venosa profunda, o embolia pulmonar sintomáticas. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. Rivaroxaban oral, una vez al día, inhibidor directo del factor Xa en la prevención a largo plazo del trombo embolismo venoso sintomático recurrente, en pacientes con trombosis venosa profunda, o embolia pulmonar sintomáticas. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
5
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
6
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
7
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
8
Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
9
Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
10
Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study : Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. - The Einstein-Extension Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Thema: Medical Condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism.
Medienart
24
Aufsätze
24
E-Artikel
24
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
24
610
Medical Condition: Long-term prevention of recu...
24
Recruitment Status: Not yet recruiting
24
Study Type: Interventional
6
Phase: Phase 3
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2019
2
2017
18
2012
Erscheinungsjahr(e)
Von:
Bis:
Sprache
24
Englisch
Haven't found what you're looking for?
Wird geladen...